Kinetic Inertness of the Mn Complexes Formed with AAZTA and Some Open-Chain EDTA Derivatives by Kálmán, Ferenc K. & Tircsó, Gyula
1 Kinetic Inertness of the Mn2+ Complexes Formed with AAZTA and
2 Some Open-Chain EDTA Derivatives
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7 ABSTRACT: The results of systematic equilibrium,
8 kinetic, and relaxometric investigations carried out on
9 the Mn2+ complexes of open-chain and AAZTA ligands
10 indicate that the [Mn(CDTA)]2− complexes have
11 satisfactorily high kinetic inertness (t1/2 = 12 h at pH =
12 7.4), which, in turn, may allow its use as a contrast agent in
13 the ﬁeld of magnetic resonance imaging (as a replacement
14 for Gd3+-based agents).
15 The recent discovery and association of the disease called16 Nephrogenic Systemic Fibrosis (NSF) with gadolinium
17 deposition originating from the use of Gd3+-based contrast
18 agents (CAs) in patients with severe renal failure or following
19 liver transplantation have pointed out that the rules of the
20 application of paramagnetic metal complexes in magnetic
21 resonance imaging (MRI) investigations have to be more
22 strict.1 Parallel with the recognition of NSF, there is a growing
23 interest in the development of the CAs in order to design safer
24 candidates. To obtain harmless CAs, one possibility is to
25 change the paramagnetic metal center for the one that is better
26 tolerated in the living systems such as Mn2+. The biogenic
27 Mn2+, with its half-ﬁlled electron shell and slow electron-spin
28 relaxation, is a good candidate to replace the Gd3+ ion in CAs
29 because it is an endogenous metal and biological systems have
30 developed eﬀective routes to control its homeostasis.2−8
31 Unfortunately, the lack of ligand-ﬁeld stabilization, which can
32 be traced back to the symmetric d5 electron conﬁguration
33 system of the Mn2+ ion, results in thermodynamically less stable
34 complexes than those of other transition metals, while its lower
35 positive charge makes the Mn2+ complexes less stable than the
36 complexes of the lanthanide ions. Additionally, even the most
37 highly stable Mn2+ complexes were found to be kinetically
38 labile, such as [Mn(DTPA)]3−.9 On the other hand, the use of
39 the only Mn2+-containing CA Mangafodipir, [Mn(DPDP)]4−,
40 is also based on its fast dissociation under in vivo conditions.10
41 In a sharp contrast to the avenue represented by open-chain
42 ligands, recent studies have shown that the kinetic inertness of
43 some Mn2+ complexes of macrocyclic ligands makes them
44 suitable for in vivo applications.4−6,11 The lack of systematic
45 investigations carried out on the Mn2+ complexes of open-chain
46 ligands made the basis of the current study. For this reason, the
47 thermodynamic stability and kinetic inertness of some Mn2+
48 complexes formed with open-chain and AAZTA ligands have
c1 49 been investigated (Chart 1). The relaxivity values of the Mn2+
50 complexes were also determined at 20 MHz magnetic ﬁeld
51strength, and a simple model calculation was carried out for the
52[Mn(CDTA)]2− complex to approximate the rate and extent of
53its dissociation in plasma.
54The stability of the complexes is characterized by the stability
55constants of the complex species and by a report on their pMn
56values deﬁned by the conditional stability constant of the
57complexes using conditions suggested recently by Drahos et al.
58(pH = 7.4; cMn = cL = 10
−5 M). The pMn values calculated for
59the Mn2+ complexes of EDTA, CDTA, TMDTA, BIMP,
60DTPA, EGTA, and AAZTA ligands are 7.83, 9.90, 5.81, 6.30,
617.95, 6.91, and 8.29, respectively. These values are similar to
62those reported for the most inert Mn compexes of macrocyclic
63ligands, NOTA and DOTA (pMn = 7.94 and 9.09 were
64calculated from the stability data reported by Cortes et al.12 and
65Bianchi et al.13 for [Mn(NOTA)]− and [Mn(DOTA)]2−,
66respectively). While these data did not diﬀer substantially, the
67kinetic inertness values of the complexes of open-chain and
68macrocyclic ligands are known to diﬀer by orders of magnitude.
69Furthermore, nowadays, the kinetic inertness is recognized to
70be a more important property of the complexes considered for
71in vivo use.
72The dissociation mechanisms of the Mn2+ complexes do not
73diﬀer basically from those of the Gd3+ complexes.4−6,11 The
74dissociation of the metal complexes applied in vivo may occur
75via the following pathways: spontaneous, acid-catalyzed, metal
76ion-initiated decomplexation (with the direct attack of the
77exchanging metal ion). Some endogenous ligand may also
78accelerate the dissociation of the complexes.14 For the
79dissociation of the Mn2+ complexes in the presence of Cu2+,
80 s1a general reaction scheme can be established (Scheme 1).
81In order to obtain information on the rate of dissociation,
82usually transmetalation reactions, which occur between the
83paramagnetic complex and a suitable exchanging metal ion such
84as Mg2+, Ca2+, Zn2+, or Cu2+, are studied. The metal-exchange
85reactions of the Mn2+ complexes were investigated by
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Chart 1. Structure of the Ligands Studied in the Current
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86 spectrophotometry, in the presence of a high (10−40-fold)
87 excess of exchanging Cu2+ ion, ensuring pseudo-ﬁrst-order
88 conditions. Under these conditions, the rate of the reaction can
89 be expressed as follows: −d[MnL]t/dt = kobs[MnL]tot, where
90 kobs is the pseudo-ﬁrst-order rate constant and [MnL]tot is the
91 total concentration of the Mn2+ complex.
92 Taking into account the diﬀerent pathways (characterized by
93 the rate constants k0, kH, kH
H, kCu, and kCu
H; Scheme 1) and the
94 equations of protonation and stability constants of the
95 intermediates (KMnHL, KMnH2L, and KMnLCu), the pseudo-ﬁrst-
96 order rate constant (kobs) can be expressed by eq 1. Equation 1
97 is a general equation for describing the rates of the metal-
98 exchange reactions of the Mn2+ complexes (more details can be
99 found in the Supporting Information).
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101 The pseudo-ﬁrst-order rate constants characterizing the
102 dissociation of the Mn2+ complexes increase with increasing
103 H+ ion concentration in almost all cases (k1 and k2) and
104 increase with increasing Cu2+ concentration (k3) or remain
105 unaﬀected by the Cu2+ concentration ([Mn(EDTA)]2−) except
106 in the case of [Mn(CDTA)]2−, where the kobs values were
107 found to be inversely proportional to the Cu2+ concentration
108 (the ﬁtting of the kobs values is shown in the Supporting
109 Information). The results of the ﬁtting are summarized and
t1 110 compared in Table 1. The data ﬁtting for the [Mn(CDTA)]2−
111 complex returned the stability constant of the dinuclear
112 intermediate, but the rate constant of the metal-assisted
113 dissociation had to be neglected. This phenomenon can be
114 explained by considering the dinuclear intermediate as a “dead-
115 end” complex.
116 Equation 1 displays the general equation used in data
117 reﬁnement; however, not all of the pathway was active for the
118studied complexes. Diﬀerent dissociation mechanisms make a
119direct comparison of the data obtained diﬃcult; therefore, the
120half-lives (t1/2) of the dissociation reactions of Mn
2+ complexes
121were calculated at physiological (pH = 7.4 and at 1 × 10−5 M
122concentration of the exchanging Cu2+ ion) conditions (Table
1231). The comparison of the t1/2 values shows that the kinetic
124inertness of the [Mn(CDTA)]2− complex is 3−5 orders of
125magnitude higher than that of the Mn2+ complexes formed with
126the other open-chain ligands, and it also dissociates more slowly
127than the [Mn(AAZTA)]2− complex. This behavior is clearly
128related to the more rigid structure of the CDTA ligand, which
129provides a compact structure and a preorganized coordination
130cavity suitable for metal-ion encapsulation. The replacement of
131the ethylene backbone in EDTA for a cyclohexyl bridge results
132an increase of the kinetic inertness by more than 2 orders of
133magnitude. The kinetic inertness (characterized by t1/2) of
134[Mn(CDTA)]2− is just 3−6 times less than values obtained in
135our group recently for the [Mn(DO2A)] complex15 and
136published by Tot́h et al. for [Mn(NOTA)]−.6
137The longer backbone of the TMDTA ligand causes an
138increase of the central chelate ring size from 5 to 6, resulting in
139an increase in the lability of the complex and a decrease in the
140kinetic inertness of its Mn2+ complex. By comparing the kinetic
141inertness of the BIMP and TMDTA complexes, one can
142conclude that the presence of the phosphinate moiety in the
143BIMP ligand does not increase signiﬁcantly the kinetic inertness
144of the Mn2+ complex while it does contribute to an increase in
145the kinetic inertness of the [Ln(BIMP)]2− complexes.16 The
146scientiﬁc explanation for this phenomena can be obtained by
147analyzing the X-ray structures of some other transition-metal-
148ion (Co2+ and Cu2+) complexes of the BIMP17,18 ligand
149because the coordination of the phosphinate moiety in these
150complexes is sterically hindered while the coordination of the
151phosphinate moiety in [Ln(BIMP)]2− complexes is accepted
152now.16
153The investigation of the metal-exchange reactions between
154the [Mn(DTPA)]3− complex and the Cu2+ ion was not possible
155even by a stopped-ﬂow technique. The presence of the highly
156basic, central amine nitrogen in the DTPA ligand decreases not
157only the conditional stability of the Mn2+ complex but also its
158kinetic inertness. This gives an explanation of why the
159dissociation of [Mn(DTPA)]3− was witnessed after its in vivo
160injection.9
161With the use of the rate constants characterizing the
162dissociation of the [Mn(CDTA)]2− complex, it is possible to
163calculate the percentage of [Mn(CDTA)]2− that would be
164dissociated in the human body after the intravenous
165administration. Assuming that the half-life of the excretion of
166the [Mn(CDTA)]2− complex is the same as that of the Gd3+
Scheme 1. Assumed Reaction Mechanisms of the
Decomplexation of the Mn2+ Complexes
Table 1. Rate Constants Characterizing the Dissociation of the Mn2+ Complexes (25 °C)
k0
(s−1) k1 (M
−1 s−1) k2 (M
−2 s−1) k3 (M
−1 s−1) k4 (M
−2 s−1)
log
KMnHL
b KMLCu t1/2
c (h)
CDTAa (4.0 ± 0.1) × 102 79 ± 13 12
EDTAa (5.2 ± 0.2) × 104 (2.3 ± 0.3) × 108 45 ± 8 7.6 × 10−2
TMDTA (2.3 ± 0.4) × 107 (8 ± 2) × 105 (3.0 ± 0.4) × 1010 4.90 (2.1 ± 0.4) × 103 2.3 × 10−5
BIMP 2.1 (5 ± 1) × 104 (2.6 ± 0.2) × 103 (2.7 ± 0.5) × 107 9.0 × 10−5
EGTA (1.9 ± 0.2) × 106 (5 ± 1) × 103 317 ± 73 1.5 × 10−3
AAZTA (3.4 ± 0.2) × 103 (5.5 ± 0.4) × 107 14 ± 2 147 ± 18 0.7
aFor [Mn(CDTA)]2−, k1 = 3.2 × 10
2 M−1 s−1 and t1/2 = 15 h, while for [Mn(EDTA)]
2−, k3 = 3.0 × 10
−1 M−1 s−1, k4 = ∼4.8 × 101 M−2 s−1, and log
KMnHL = 3.10 were found in ref 19.
bDetermined by pH-pot. cpH = 7.4 and c(Cu2+) = 1 × 10−5 M were used in the calculations.
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167 complexes used in MRI (1.6 h at 37 °C), the rate of the
168 excretion can be given by a ﬁrst-order rate constant of ke =
169 0.433 h−1. The kobs value characterizing the decomplexation of
170 the [Mn(CDTA)]2− complex at physiological conditions (kd)
171 can be calculated by means of the k1 and KMnLCu values
172 determined in the metal-exchange reactions. The value of kd is
173 5.72 × 10−2 h−1.
174 The excretion of [Mn(CDTA)]2− from the body through the
175 kidneys and the dissociation of the complex could be regarded
176 as parallel ﬁrst-order reactions. For such reactions, the ratio of
177 the concentrations of the products depends on the ratio of the
178 ﬁrst-order rate constants (Supporting Information). For the
179 [Mn(CDTA)]2− complex, the ratio would be kd/(kd + ke) =
180 0.117 after 6−7 half-lives of the excretion, which means that
181 11.7% of the [Mn(CDTA)]2− complex would dissociate the
182 injected dose. Although the amount of the released Mn2+ ion
183 from the [Mn(CDTA)]2− complex is approximately 7 times
184 higher than that calculated for the [Gd(DTPA)]2− complex,
185 1.71%, the living system has routes to eliminate the released
186 Mn2+ ion like in the case of [Mn(DPDP)]4−, so [Mn-
187 (CDTA)]2− can be regarded as an acceptable CA for in vivo
188 applications.10 Experiments performed in human blood serum
189 are in agreement with the results of the kinetic studies
190 (Supporting Information).
191 The relaxivity values [the relaxivity (r1,2, mM
−1 s−1) is the
192 relaxation enhancement in the 1 mM solution of the
193 paramagnetic metal complex] of [Mn(EDTA)]2−, [Mn-
194 (CDTA)]2−, [Mn(TMDTA)]2−, [Mn(DTPA)]3−, [Mn-
195 (BIMP)]2−, [Mn(EGTA)]2−, and [Mn(AAZTA)]2−20 were
196 determined and found to be 3.2, 3.6, 2.2, 1.7, 2.1, 1.6, and 1.620
197 mM−1 s−1, respectively. From these data, we concluded that
198 EDTA and CDTA form monoaquated (q = 1) complexes with
199 the Mn2+ ion, which is highly desired for in vivo applications.
200 The results of our studies indicate that not all of the Mn2+
201 complexes of open-chain ligands are kinetically labile. It has
202 been proven that some rigid open-chain ligands modeled by the
203 tetraacetate derivative of cyclohexylene diamine (e.g., CDTA)
204 can form a kinetically inert complex with the Mn2+ ion. The
205 most promising Mn2+ complex, formed with a macrocyclic
206 ligand that possesses at least one inner-sphere water molecule
207 and therefore has high relaxivity, is the [Mn(15-py-aneN5)]
2+,5
208 but it is thermodynamically less stable than [Mn(CDTA)]2−
209 and the ligand commercially not accessible. Obviously, more
210 studies are needed to design ligands for Mn2+ complexation
211 that would display high thermodynamic stability, acceptable
212 kinetic inertness, and proper water-exchange rates, which, in
213 turn, allows one to obtain high relaxivities. Among the open-
214 chain ligands studied, clearly CDTA display the best features
215 for the in vivo applications.
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(7) 248Kubicek, V.; Éva, T. Advances in Inorganic Chemistry; Academic
249Press: New York, 2009; pp 63−129.
(8) 250Murakami, T.; Baron, R. L.; Peterson, M. S.; Oliver, J. H.; Davis,
251L.; Confer, R.; Federle, M. P. Z. Radiology 1996, 200, 69−77.
(9) 252Gallez, B.; Baudelet, C.; Geurts, M. Magn. Reson. Imaging 1998,
25316, 1211−1215.
(10) 254Rocklage, S. M.; Cacheris, W. P.; Quay, S. C.; Hahn, F. E.;
255Raymond, K. N. Inorg. Chem. 1989, 28, 477−485.
(11) 256Drahos, B.; Pniok, M.; Havlickova, J.; Kotek, J.; Cisarova, I.;
257Hermann, P.; Lukes, I.; Toth, E. Dalton Trans. 2011, 40, 10131−
25810146.
(12) 259Cortes, S.; Brucher, E.; Geraldes, C. F. G. C.; Sherry, A. D. Inorg.
260Chem. 1990, 29, 5−9.
(13) 261Bianchi, A.; Calabi, L.; Giorgi, C.; Losi, P.; Mariani, P.; Palano,
262D.; Paoli, P.; Rossi, P.; Valtancoli, B. J. Chem. Soc., Dalton Trans. 2001,
263917−922.
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(15) 267Garda, Z.; Kaĺmań, F. K.; Timaŕi, S.; Tot́h, I.; Kovaćs Z.; Tircso,́
268G. Manuscript in preparation.
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